Document is current

Article History

Received: 11 May 2023

Accepted: 28 October 2023

First Online: 10 November 2023

Declarations

:

: All THAOS sites received ethical or institutional review board approval prior to patient enrollment, and each patient provided written informed consent. The study followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki.

: Not applicable.

: Luca Gentile reports travel grants from Kedrion and CSL Behring to attend scientific meetings. Teresa Coelho reports serving as a medical advisor for Pfizer and receiving funding for scientific meeting expenses (travel, accommodation and registration) from Pfizer. Angela Dispenzieri reports research grants from Celgene, Millennium, Pfizer, Janssen and Alnylam; funding from Pfizer for meeting expenses (travel); and attending advisory boards for Akcea and Intellia. Isabel Conceição reports consulting fees and funding for scientific meeting expenses (travel, accommodation and registration) from Pfizer. Márcia Waddington-Cruz reports research funding, consulting fees and travel support for advisory boards and meetings from FoldRx Pharmaceuticals and Pfizer. Arnt V. Kristen reports reimbursement for study visits from Pfizer during the conduct of the study. Jonas Wixner reports consulting fees and travel support for lectures and advisory boards from Pfizer and Alnylam; and consulting fees from Akcea and Intellia. Igor Diemberger received speaker fees from Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, Pfizer and Philips outside the submitted work. Juan Gonzalez-Moreno reports speaker fees from Pfizer, Alnylam and Akcea. Eve Cariou has no conflicts to report. Mathew S. Maurer reports grants from Pfizer during the conduct of the study; grants and personal fees from Pfizer, Eidos, Prothena and Ionis; grants from Alnylam; and personal fees from GSK and Akcea outside the submitted work. Violaine Planté-Bordeneuve reports serving as a medical advisor for Pfizer, Alnylam, Eidos and Ionis. Pablo Garcia-Pavia reports speaking fees from Pfizer, Eidos, Alnylam and Akcea; consulting fees from Pfizer, Eidos, Neurimmune, Alnylam, Prothena and Akcea; and research/educational support to his institution from Pfizer, Eidos and Alynylam. Ivailo Tournev reports speakers bureau/lecturer fees from Ewopharma, Genesis Pharma, Pfizer, Roche and Sanofi. Jose Gonzalez-Costello reports attending advisory boards for Pfizer and Alnylam. Alejandra González-Duarte reports financial support from Alnylam and Pfizer for her role as a principal investigator in studies sponsored by these entities, and as a consultant and speaker. Martha Grogan reports grants and advisory board and consultancy fees paid to her institution from Alnylam, Eidos, Prothena and Pfizer. Anna Mazzeo reports financial grants (honoraria and speaking) from Ackea, Alnylam, and Pfizer. Doug Chapman, Pritam Gupta, Oliver Glass, and Leslie Amass are current or former employees of Pfizer and hold stock and/or stock options in Pfizer.